Cell-Based Therapy for Retinal Disease: The New Frontier

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The availability of noninvasive high-resolution imaging technology, the immune-suppressive nature of the subretinal space, and the existence of surgical techniques that permit transplantation surgery to be a safe procedure all render the eye an ideal organ in which to begin cell-based therapy in the central nervous system. A number of early stage clinical trials are underway to assess the safety and feasibility of cell-based therapy for retinal blindness. Cell-based therapy using embryonic stem cell-derived differentiated cells (e.g., retinal pigment epithelium (RPE)), neural progenitor cells, photoreceptor precursors, and bone marrow-derived hematopoietic stem/progenitor cells has demonstrated successful rescue and/or replacement in preclinical models of human retinal degenerative disease. Additional research is needed to identify the mechanisms that control synapse formation/disjunction (to improve photoreceptor transplant efficacy), to identify factors that limit RPE survival in areas of geographic atrophy (to improve RPE transplant efficacy in eyes with age-related macular degeneration), and to identify factors that regulate immune surveillance of the subretinal space (to improve long-term photoreceptor and RPE transplant survival).

LanguageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages367-381
Number of pages15
DOIs
StatePublished - Jan 1 2019

Publication series

NameMethods in Molecular Biology
Volume1834

Fingerprint

Retinal Diseases
Retinal Pigment Epithelium
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Transplants
Geographic Atrophy
Macular Degeneration
Immunologic Factors
Blindness
Embryonic Stem Cells
Synapses
Stem Cells
Central Nervous System
Transplantation
Bone Marrow
Clinical Trials
Technology
Safety
Research

Cite this

Zarbin, M. (2019). Cell-Based Therapy for Retinal Disease: The New Frontier. In Methods in Molecular Biology (pp. 367-381). (Methods in Molecular Biology; Vol. 1834). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-8669-9_23
Zarbin, Marco. / Cell-Based Therapy for Retinal Disease : The New Frontier. Methods in Molecular Biology. Humana Press Inc., 2019. pp. 367-381 (Methods in Molecular Biology).
@inbook{23240fb1232447b2880191c011097073,
title = "Cell-Based Therapy for Retinal Disease: The New Frontier",
abstract = "The availability of noninvasive high-resolution imaging technology, the immune-suppressive nature of the subretinal space, and the existence of surgical techniques that permit transplantation surgery to be a safe procedure all render the eye an ideal organ in which to begin cell-based therapy in the central nervous system. A number of early stage clinical trials are underway to assess the safety and feasibility of cell-based therapy for retinal blindness. Cell-based therapy using embryonic stem cell-derived differentiated cells (e.g., retinal pigment epithelium (RPE)), neural progenitor cells, photoreceptor precursors, and bone marrow-derived hematopoietic stem/progenitor cells has demonstrated successful rescue and/or replacement in preclinical models of human retinal degenerative disease. Additional research is needed to identify the mechanisms that control synapse formation/disjunction (to improve photoreceptor transplant efficacy), to identify factors that limit RPE survival in areas of geographic atrophy (to improve RPE transplant efficacy in eyes with age-related macular degeneration), and to identify factors that regulate immune surveillance of the subretinal space (to improve long-term photoreceptor and RPE transplant survival).",
author = "Marco Zarbin",
year = "2019",
month = "1",
day = "1",
doi = "https://doi.org/10.1007/978-1-4939-8669-9_23",
language = "English (US)",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "367--381",
booktitle = "Methods in Molecular Biology",

}

Zarbin, M 2019, Cell-Based Therapy for Retinal Disease: The New Frontier. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 1834, Humana Press Inc., pp. 367-381. https://doi.org/10.1007/978-1-4939-8669-9_23

Cell-Based Therapy for Retinal Disease : The New Frontier. / Zarbin, Marco.

Methods in Molecular Biology. Humana Press Inc., 2019. p. 367-381 (Methods in Molecular Biology; Vol. 1834).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Cell-Based Therapy for Retinal Disease

T2 - The New Frontier

AU - Zarbin, Marco

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The availability of noninvasive high-resolution imaging technology, the immune-suppressive nature of the subretinal space, and the existence of surgical techniques that permit transplantation surgery to be a safe procedure all render the eye an ideal organ in which to begin cell-based therapy in the central nervous system. A number of early stage clinical trials are underway to assess the safety and feasibility of cell-based therapy for retinal blindness. Cell-based therapy using embryonic stem cell-derived differentiated cells (e.g., retinal pigment epithelium (RPE)), neural progenitor cells, photoreceptor precursors, and bone marrow-derived hematopoietic stem/progenitor cells has demonstrated successful rescue and/or replacement in preclinical models of human retinal degenerative disease. Additional research is needed to identify the mechanisms that control synapse formation/disjunction (to improve photoreceptor transplant efficacy), to identify factors that limit RPE survival in areas of geographic atrophy (to improve RPE transplant efficacy in eyes with age-related macular degeneration), and to identify factors that regulate immune surveillance of the subretinal space (to improve long-term photoreceptor and RPE transplant survival).

AB - The availability of noninvasive high-resolution imaging technology, the immune-suppressive nature of the subretinal space, and the existence of surgical techniques that permit transplantation surgery to be a safe procedure all render the eye an ideal organ in which to begin cell-based therapy in the central nervous system. A number of early stage clinical trials are underway to assess the safety and feasibility of cell-based therapy for retinal blindness. Cell-based therapy using embryonic stem cell-derived differentiated cells (e.g., retinal pigment epithelium (RPE)), neural progenitor cells, photoreceptor precursors, and bone marrow-derived hematopoietic stem/progenitor cells has demonstrated successful rescue and/or replacement in preclinical models of human retinal degenerative disease. Additional research is needed to identify the mechanisms that control synapse formation/disjunction (to improve photoreceptor transplant efficacy), to identify factors that limit RPE survival in areas of geographic atrophy (to improve RPE transplant efficacy in eyes with age-related macular degeneration), and to identify factors that regulate immune surveillance of the subretinal space (to improve long-term photoreceptor and RPE transplant survival).

UR - http://www.scopus.com/inward/record.url?scp=85054890699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054890699&partnerID=8YFLogxK

U2 - https://doi.org/10.1007/978-1-4939-8669-9_23

DO - https://doi.org/10.1007/978-1-4939-8669-9_23

M3 - Chapter

T3 - Methods in Molecular Biology

SP - 367

EP - 381

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -

Zarbin M. Cell-Based Therapy for Retinal Disease: The New Frontier. In Methods in Molecular Biology. Humana Press Inc. 2019. p. 367-381. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-8669-9_23